CAS: 100-19-6; 1-(4-Nitrophenyl)Ethanone

上下游产品

CAS号149104-90-5 4-乙酰苯硼酸 | CAS号100-12-9 对乙基硝基苯 | CAS号937-31-5 4-硝基苯乙炔 | CAS号19935-81-0 1-(1-溴乙基)-4-硝基苯 | CAS号6531-13-1 1-(4-硝基苯基)乙醇 | CAS号67395-06-6 2-methyl-2-(4-n... | CAS号41780-82-9 4-methyl-N'-(1-... | CAS号19073-15-5 2-methyl-2-(4-n... | CAS号77635-72-4 4-nitroacetophe... | CAS号58896-24-5 Ethanone,1-(4-n... | CAS号108791-66-8 1,4-双(4-硝基苯基)丁-... | CAS号106098-23-1 (Z)-3-氯-3-(4-硝基... | CAS号10517-47-2 Ethanone,1-[4-(... | CAS号6531-13-1 1-(4-硝基苯基)乙醇 | CAS号99-92-3 4-氨基苯乙酮 | CAS号18179-86-7 4',4'''-Azobisa... | CAS号104755-32-0 1-(4-nitropheny... | CAS号111358-84-0 6-(4-nitropheny... | CAS号110944-98-4 2-iodo-1-(4-nit... | CAS号1000375-34-7 1-(2-iodo-1,1-d...

4-硝基苯乙烯置于ferric Sulfate Heptahydrate,Palladium Dichloride体系中,用 水,乙腈 用作溶剂,化学反应 14.0H,以55%的收率获得对硝基苯乙酮
参考文献:瓦克氧化法合成甲基酮时,硫酸铁(III)作为末端氧化剂
标题:瓦克氧化法合成甲基酮时,硫酸铁(III)作为末端氧化剂
摘要:开发了一种有效的,环境友好的方法,该方法在通过wacker方法从末端烯烃合成甲基酮的过程中,使用硫酸fe(III)作为末端氧化剂.该方法为markonikov产品提供了高选择性,显示出非常好的官能团相容性,涉及温和的反应条件,并且操作简单.在此过程中,Fe 2(so 4)3是唯一的末端氧化剂.该方法具有在有机合成中未来应用的潜力.
Doi:10.1021/jo500921J

专利信息

专利号:US-11512303-B2
优先权日:2017-05-27
标 题 :Engineered polypeptides and their applications in the synthesis of beta-hydroxy-alpha-amino acids
发明人：CHEN HAIBIN; BONG YONG KOY; XU QING; ZHOU AMENG; SHEN TIANRAN; YANG JIADONG; YANG ZHUHONG
权利人:ENZYMASTER NINGBO BIO ENG CO LTD
摘要:The present invention provides engineered polypeptides that are useful for the asymmetric synthesis of β-hydroxy-α-amino acids under industrial-relevant conditions. The engineered polypeptides disclosed in this invention were developed through directed evolution based on the ability of catalytic synthesis of (2S, 3R)-2-amino-3-hydroxy-3-(4-nitrophenyl) propanoic acid. The present disclosure also provides polynucleotides encoding engineered polypeptides, host cells capable of expressing engineered polypeptides, and methods of producing β-hydroxy-α-amino acids using engineered polypeptides. Compared to other processes of preparation, the use of the engineered polypeptides of the present invention for the preparation of β-hydroxy-α-amino acids results in high purity of the desired stereoisomers, mild reaction conditions, low pollution and low energy consumption. So, it has good industrial application prospects.

专利号:US-11078465-B2
优先权日:2018-02-12
标题:Alcohol dehydrogenase mutant and application thereof in synthesis of diaryl chiral alcohols
发明人：NI YE; WANG YUE; DAI WEI; XU GUOCHAO; ZHOU JIEYU
权利人:UNIV JIANGNAN
摘要:The present disclosure discloses an alcohol dehydrogenase mutant and application thereof in synthesis of diaryl chiral alcohols, and belongs to the technical field of bioengineering. The alcohol dehydrogenase mutant of the present disclosure has excellent catalytic activity and stereoselectivity, and may efficiently catalyze the preparation of a series of chiral diaryl alcohols in R- and S-configurations. By coupling alcohol dehydrogenase of the present disclosure to glucose dehydrogenase or formate dehydrogenase, the synthesis of chiral diaryl alcohol intermediates of various antihistamines may be achieved. Compared with the prior art, a method for preparing diaryl chiral alcohols through asymmetric catalytic reduction using the alcohol dehydrogenase of the present disclosure has the advantages of simple and convenient operation, high substrate concentration, complete reaction and high product purity, and has great industrial application prospects.

专利号:US-10487099-B2
优先权日:2017-06-30
标 题:Synthesis of hypervalent iodine reagents with dioxygen
发明人：POWERS DAVID CHARLES; MAITY ASIM; HYUN SUNG-MIN
权利人:TEXAS A & M UNIV SYS
摘要:Methods of synthesis of hypervalent iodine reagents and methods for oxidation of organic compounds are disclosed.

专利号:US-6620942-B2
优先权日:1998-12-23
标题 :Synthesis of histamine dihydrochloride
发明人：YEH WEN-LUNG; ANTCZAK CASIMIR; MCGOLRICK JEFFRY DAVID; ROTH MICHAEL JOSEPH; WRONA MARK
权利人:MAXIM PHARMACEUTICALS
摘要:The invention disclosed herein relates to the preparation of pharmaceutical grades of histamine dihydrochloride using a two step non-enzymatic synthetic method. The invention disclosed herein describes the synthesis of histamine dihydrochloride by the non-enzymatic decarboxylation of histidine and the step-wise conversion of the decarboxylated product to the dihydrochloride salt form. The invention disclosed herein considers a final product of histamine dihydrochloride containing less than each of the following: 0.8% L -histidine HCl monohydrate, 0.1% individual chromatographic impurities, and 2% total impurities, to be acceptable for pharmaceutical use.

专利号:US-2022098155-A1
优先权日:2018-11-14
标 题 :Novel pathway for the synthesis of diazirines, that may or may not be enriched in nitrogen-15
发明人：REBOUL VINCENT; FRANCK XAVIER; GLACHET THOMAS; MARZAG HAMID
权利人:UNIV ROUEN NORMANDIE; UNIV CAEN; INSTITUT NAT DES SCIENCES APPLIQUEES DE ROUEN INSA; CENTRE NAT RECH SCIENT; ECOLE NAT SUPERIEURE DINGENIEURS DE CAEN
摘要:The present invention concerns a novel method for synthesising diazirines, that may or may not be enriched in nitro-gen-15, from amino acids or imines, via a one-pot synthesis method, comprising the reaction of the starting amino acid or imine with ammonia, which may or may not be enriched in nitrogen-15, and a hypervalent iodine oxidant. The present invention also relates to a method for synthesising ammonia enriched in nitrogen-15. The invention also concerns certain diazirines of formula (I) likely to be obtained by the claimed synthesis method, and also refers to the 15 N 2 -diazirines of formula (I′). The claimed diazirines can be used in photoaffinity labelling. The 15 N 2 -diazirines can also be used in hyperpolarisation, in particular in the medical imaging field.

专利号:US-2022356182-A1
优先权日:2009-03-27
标题 :Inhibitors of hepatitis c virus replication
发明人：COBURN CRAIG A; LUDMERER STEVEN W; LIU KUN; WU HAO; SOLL RICHARD; ZHONG BIN; ZHU JIAN
权利人:MERCK SHARP & DOHME
摘要:The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.